Pfizer’s Ibrance fails breast cancer trial

(Reuters) – Pfizer Inc said on Friday its cancer drug Ibrance did not meet the main goal in a late-stage trial in women with a type of breast cancer.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)